Answers are grounded in this paper and cite their sources.
Medical surveillance for CBD identifies individuals at significant risk of disease progression and impairment with sufficient time since first exposure.
No takes yet. Share an insight, caveat, or question.
Mroz et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: